An Observational Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) And Oxaliplatin in Patients With Colorectal Cancer

Roche

Status: Completed

Conditions: Colorectal Cancer

Treatments: Biological: Capecitabine; Drug: Oxaliplatin; Biological: Bevacizumab

Study type: Observational

Funder types: Industry

Identifiers

NCT01399190

ML25523

Details and patient eligibility

About

This prospective observational study will evaluate the efficacy and safety of bevacizumab in combination with capecitabine and oxaliplatin as first-line treatment in participants with colorectal cancer. Data will be collected from each participant until disease progression occurs (for up to 30 months).

Enrollment: 68 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients, >/= 18 years of age
• Metastatic colorectal cancer
• Treatment in accordance with current Summary of Product Characteristics and local guidelines

Exclusion criteria

• Contraindications according to current Summary of Product Characteristics and local guidelines

Trial design

68 participants in 1 patient group

Bevacizumab

Description:

Participants will receive bevacizumab in combination with capecitabine and oxaliplatin.

Treatment:

Biological: Bevacizumab

Drug: Oxaliplatin

Biological: Capecitabine